{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:27Z","timestamp":1787950047947,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40264-024-01427-3","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:02:08Z","timestamp":1714496528000},"page":"711-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study"],"prefix":"10.1007","volume":"47","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-7881","authenticated-orcid":false,"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"5","key":"1427_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1684\/ejd.2012.1802","volume":"22","author":"X Ding","year":"2012","unstructured":"Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663\u20137.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1427_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JD9.0000000000000074","volume":"3","author":"Committee of Psoriasis, Chinese Medical Association","year":"2020","unstructured":"Committee of Psoriasis, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition#. Int J Dermatol Venereol. 2020;3(1):14\u201326.","journal-title":"Int J Dermatol Venereol"},{"issue":"28","key":"1427_CR3","doi-asserted-by":"publisher","first-page":"46381","DOI":"10.18632\/oncotarget.18453","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, Wang G, Jin H, Xu J, Zhu X, Zheng M, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8(28):46381\u20139.","journal-title":"Oncotarget"},{"key":"1427_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8: 743180.","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"1427_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","volume":"13","author":"A Buja","year":"2023","unstructured":"Buja A, Miatton A, Cozzolino C, Brazzale AR, Lo Bue R, Mercuri SR, et al. The prevalent comorbidome at the onset of psoriasis diagnosis. Dermatol Ther (Heidelb). 2023;13(9):2093\u2013105.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"1427_CR6","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/jdv.15539","volume":"33","author":"G Damiani","year":"2019","unstructured":"Damiani G, Cazzaniga S, Conic RR, Naldi L. Pruritus characteristics in a large italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"9993","key":"1427_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"1427_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"key":"1427_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000244","author":"X Li","year":"2022","unstructured":"Li X, Zheng J, Pan W, Zheng M, Lu Y, Li F, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venereol. 2022. https:\/\/doi.org\/10.1097\/JD9.0000000000000244.","journal-title":"Int J Dermatol Venereol"},{"issue":"3","key":"1427_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40257-019-00490-2","volume":"21","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1427_CR12","first-page":"5464","volume":"40","author":"L Ying","year":"2023","unstructured":"Ying L, Suyun J, Yanhua L, Yunsheng L, Li D, Lin D, et al. Safety and efficacy of ixekizumab in chinese adults with moderate-to-severe plaque psoriasis: a prospective, multicenter, observational study. Adv Ther. 2023;40(12):5464\u201374.","journal-title":"Observational Study. Adv Ther."},{"issue":"3","key":"1427_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","volume":"10","author":"C Leonardi","year":"2020","unstructured":"Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10(3):431\u201347.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1427_CR14","unstructured":"National Institute on Aging (NIA) Adverse Event and Serious Adverse Event Guidelines. Available from: https:\/\/www.nia.nih.gov\/sites\/default\/files\/2018-09\/nia-ae-and-sae-guidelines-2018.pdf."},{"key":"1427_CR15","unstructured":"ICH E2A Clinical safety data management: definitions and standards for expedited reporting - Scientific guideline. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting-scientific-guideline."},{"issue":"1","key":"1427_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","volume":"147","author":"M Robles-Diaz","year":"2014","unstructured":"Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109-18e5.","journal-title":"Gastroenterology"},{"issue":"2","key":"1427_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1427_CR18","unstructured":"Eli Lilly and Company (Ireland) Limited. Talx (ixekizumab) European Summary of Product Characteristics (February 2023). [cited March 2023]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf"},{"key":"1427_CR19","unstructured":"https:\/\/psoriasiscouncil.org\/industry\/citrate-free-ixekizumab\/. Accessed 15 Sep 2023."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01427-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:23:09Z","timestamp":1718608989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01427-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01427-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"18 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.C. and J.L. are employees of Eli Lilly China. The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted with respect for the individual participants according to the protocol, the World Medical Association Declaration of Helsinki, the ICH-GCP guideline, and applicable local regulatory requirements of each participating region. The study was approved by Independent Ethics Committees at each study center (see electronic supplementary material, Table ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written, informed consent prior to participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data can be made available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"L.Y. and D.L. contributed to design of the work, acquisition of data for the work, interpretation of data for the work and critical revision of the work for important intellectual content. S.Y.L. contributed to conception of the work, acquisition of data for the work, interpretation of data for the work and critical revision of the work for important intellectual content. L.Y.S., L.Y.H., L.C.Z., L.B.J., T.J., Y.N., D.Y., W.H.P., K.X.J., and Q.H. contributed to acquisition of data for the work and critical revision of the work for important intellectual content. C.R. and L.J.N. contributed to interpretation of data for the work and critical revision of the work for important intellectual content. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}